Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Leukemia. 2018 Oct 12;33(2):554–558. doi: 10.1038/s41375-018-0274-y

TABLE 1.

Characteristics of study cohort

S8600
(n=530)		 S9031/S9333
(n=156)		 S0106
(n=301)		 S1203
(n=261)		 P-value
Median age, years (range) 45 (15–64) 61 (56–65) 48 (18–60) 48 (19–60) <0.001
Gender, n (%)
 Female
 Male
247 (47)
283 (53)
70 (45)
86 (55)
147 (49)
154 (51)
131 (50)
130 (50)		 0.68
Performance status, n (%)
 0–1
 2–4
374 (73)
140 (27)
114 (75)
38 (25)
255 (85)
44 (15)
221 (85)
40 (15)		 <0.001
Cytogenetic risk, n (%)
 Favorable
 Intermediate
 Unfavorable
 Missing
9 (9)
56 (58)
32 (33)
97
5 (5)
68 (62)
36 (33)
109
42 (19)
126 (57)
55 (25)
223
28 (11)
168 (66)
60 (23)
256		 0.0035
NPM1, FLT3/ITD status, n (%)
 NPM1- and/or FLT3/ITD+
 NPM1+ and FLT3-
 NPM1, FLT3/ITD unknown		 N/A
 N/A
153 (84)
30 (16)
183
144 (85)
25 (15)
169		 0.76
Type of AML, n (%)
 De novo
 Secondary
506 (95)
24 (5)
122 (78)
34 (22)
301 (100)
0 (0)
236 (90)
25 (10)		 <0.001
Laboratory studies at baseline
 WBC (x103/µL), median (range)
 Platelets (x103/µL)
 Marrow blasts (%)
18 (0–416)
54 (2–700)
74 (0–99)
13 (1–274)
49 (6–1,200)
61 (10–99)
12 (0–244)
55 (7–9,300)
66 (3–100)
13 (1–800)
50 (4–8,500)
60 (0–100)
0.029
0.045
<0.001
Number of induction courses, n (%)
 1
 2
381 (72)
149 (28)
126 (82)
27 (18)
234 (78)
66 (22)
198 (76)
63 (24)		 0.036
Induction response, n (%)
 CR on first induction
 CR on reinduction
 No CR
219 (41)
68 (13)
243 (46)
74 (48)
7 (5)
72 (47)
178 (59)
32 (11)
91 (30)
137 (52)
27 (10)
97 (37)		 <0.001